What was the market valuation of the US pituitary cancer market in 2024?

The market valuation of the US pituitary cancer market was $70.63 Million in 2024. Read More

What is the projected market valuation for the US pituitary cancer market by 2035?

The projected market valuation for the US pituitary cancer market is $173.08 Million by 2035. Read More

What is the expected CAGR for the US pituitary cancer market during the forecast period 2025 - 2035?

The expected CAGR for the US pituitary cancer market during the forecast period 2025 - 2035 is 8.49%. Read More

Which companies are key players in the US pituitary cancer market?

Key players in the US pituitary cancer market include Novartis, Pfizer, Bristol-Myers Squibb, Eli Lilly and Company, AstraZeneca, Merck & Co., Roche, Amgen, and Sanofi. Read More

What are the revenue ranges for different types of pituitary tumors in the market?

Revenue ranges for different types of pituitary tumors include: ACTH Tumor ($10.0 - $25.0 Million), Growth Hormone-Secreting Tumor ($15.0 - $40.0 Million), Prolactin-Secreting Tumor ($20.0 - $50.0 Million), and Thyroid-Stimulating Hormone-Secreting Tumor ($25.63 - $58.08 Million). Read More

What treatment types are available in the US pituitary cancer market and their revenue ranges?

Treatment types and their revenue ranges include: Chemotherapy ($5.0 - $12.0 Million), Surgery ($15.0 - $35.0 Million), Endoscopic Trans Nasal Transsphenoidal Surgery ($10.0 - $25.0 Million), and Radiation Therapy ($12.0 - $30.0 Million). Read More

What are the revenue contributions of different end-users in the US pituitary cancer market?

Revenue contributions from different end-users include: Hospitals & Clinics ($30.31 - $75.0 Million), Specialty Clinics ($25.25 - $60.0 Million), and Others ($15.07 - $38.08 Million). Read More

How does the market for Prolactin-Secreting Tumors compare to other tumor types?

The market for Prolactin-Secreting Tumors shows a revenue range of $20.0 - $50.0 Million, indicating a competitive position among other tumor types. Read More

What is the significance of the projected growth in the US pituitary cancer market?

The projected growth in the US pituitary cancer market suggests a rising demand for innovative treatments and increased investment in research and development. Read More

How do the revenue ranges for surgical treatments compare to other treatment types?

Surgical treatments, with a revenue range of $15.0 - $35.0 Million, appear to be among the higher revenue-generating treatment types compared to others like Chemotherapy and Radiation Therapy. Read More

US Pituitary Cancer Market

ID: MRFR/Pharma/17462-HCR

100 Pages

Nidhi Mandole

Last Updated: April 06, 2026

US Pituitary Cancer Market Research Report By Cancer Type (Adrenocorticotropic Hormone-Secreting (ACTH) Tumor, Growth Hormone-Secreting Tumor, Prolactin-Secreting Tumor, Thyroid-Stimulating Hormone-Secreting Tumor), By Treatment Type (Chemotherapy, Surgery, Endoscopic Trans Nasal Transsphenoidal Surgery, Craniotomy, Radiation Therapy, Stereotactic Radiosurgery, External Beam Radiation, Intensity-Modulated Radiation Therapy (IMRT), Proton Beam Therapy, Others) and By End User (Hospitals & Clinics, Specialty Clinics, Others) - Growth & Industry Forecast 2025 To 2035

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Chemicals and Materials, BY Type (USD Million)
  1. 4.1.1 Adrenocorticotropic Hormone-Secreting (ACTH) Tumor
  2. 4.1.2 Growth Hormone-Secreting Tumor
  3. 4.1.3 Prolactin-Secreting Tumor
  4. 4.1.4 Thyroid-Stimulating Hormone-Secreting Tumor
2. 4.2 Chemicals and Materials, BY Treatment Type (USD Million)
  1. 4.2.1 Chemotherapy
  2. 4.2.2 Surgery
  3. 4.2.3 Endoscopic Trans Nasal Transsphenoidal Surgery
  4. 4.2.4 Craniotomy
  5. 4.2.5 Radiation Therapy
  6. 4.2.6 Stereotactic Radiosurgery
  7. 4.2.7 External Beam Radiation
  8. 4.2.8 Intensity-Modulated Radiation Therapy (IMRT)
  9. 4.2.9 Proton Beam Therapy
  10. 4.2.10 Others
3. 4.3 Chemicals and Materials, BY End-User (USD Million)
  1. 4.3.1 Hospitals & Clinics
  2. 4.3.2 Specialty Clinics
  3. 4.3.3 Others
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Chemicals and Materials
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Chemicals and Materials
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Novartis (CH)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Pfizer (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Bristol-Myers Squibb (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Eli Lilly and Company (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 AstraZeneca (GB)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Merck & Co. (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Roche (CH)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Amgen (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Sanofi (FR)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 US MARKET ANALYSIS BY TYPE
3. 6.3 US MARKET ANALYSIS BY TREATMENT TYPE
4. 6.4 US MARKET ANALYSIS BY END-USER
5. 6.5 KEY BUYING CRITERIA OF CHEMICALS AND MATERIALS
6. 6.6 RESEARCH PROCESS OF MRFR
7. 6.7 DRO ANALYSIS OF CHEMICALS AND MATERIALS
8. 6.8 DRIVERS IMPACT ANALYSIS: CHEMICALS AND MATERIALS
9. 6.9 RESTRAINTS IMPACT ANALYSIS: CHEMICALS AND MATERIALS
10. 6.10 SUPPLY / VALUE CHAIN: CHEMICALS AND MATERIALS
11. 6.11 CHEMICALS AND MATERIALS, BY TYPE, 2024 (% SHARE)
12. 6.12 CHEMICALS AND MATERIALS, BY TYPE, 2024 TO 2035 (USD Million)
13. 6.13 CHEMICALS AND MATERIALS, BY TREATMENT TYPE, 2024 (% SHARE)
14. 6.14 CHEMICALS AND MATERIALS, BY TREATMENT TYPE, 2024 TO 2035 (USD Million)
15. 6.15 CHEMICALS AND MATERIALS, BY END-USER, 2024 (% SHARE)
16. 6.16 CHEMICALS AND MATERIALS, BY END-USER, 2024 TO 2035 (USD Million)
17. 6.17 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TYPE, 2025-2035 (USD Million)
  2. 7.2.2 BY TREATMENT TYPE, 2025-2035 (USD Million)
  3. 7.2.3 BY END-USER, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

US Chemicals and Materials Market Segmentation

Chemicals and Materials By Type (USD Million, 2025-2035)

Adrenocorticotropic Hormone-Secreting (ACTH) Tumor
Growth Hormone-Secreting Tumor
Prolactin-Secreting Tumor
Thyroid-Stimulating Hormone-Secreting Tumor

Chemicals and Materials By Treatment Type (USD Million, 2025-2035)

Chemotherapy
Surgery
Endoscopic Trans Nasal Transsphenoidal Surgery
Craniotomy
Radiation Therapy
Stereotactic Radiosurgery
External Beam Radiation
Intensity-Modulated Radiation Therapy (IMRT)
Proton Beam Therapy
Others

Chemicals and Materials By End-User (USD Million, 2025-2035)

Hospitals & Clinics
Specialty Clinics
Others

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”